Author:
Lin Jing,Wang Tong-Fei,Huang Mei-Juan,Huang Hao-Bo,Chen Pei-Fang,Zhou Yu,Dai Wei-Chao,Zhou Ling,Feng Xiu-Shan,Wang Hui-Lan
Abstract
Abstract
Background
Treatment options for pregnant women with immune thrombocytopenia (ITP) who do not respond to first-line treatment are limited. Few studies have reported the use of recombinant human thrombopoietin (rhTPO) for this subset of patients.
Aims
To investigate the efficacy and safety of rhTPO in ITP during pregnancy and determine obstetric outcomes and predictors of treatment response.
Methods
From July 2013 to October 2022, the data of 81 pregnant women with ITP and a platelet count < 30 × 109/L who did not respond to steroids and/or intravenous immunoglobulin were retrospectively analysed. Of these patients, 33 received rhTPO treatment (rhTPO group) while 48 did not (control group). Baseline characteristics, haematological disease outcomes before delivery, obstetric outcomes, and adverse events were compared between groups. In the rhTPO group, a generalised estimating equation (GEE) was used to investigate the factors influencing the response to rhTPO treatment.
Results
The baseline characteristics were comparable between both groups (P > 0.05, both). Compared with controls, rhTPO patients had higher platelet counts (median [interquartile range]: 42 [21.5–67.5] vs. 25 [19–29] × 109/L, P = 0.002), lower bleeding rate (6.1% vs. 25%, P = 0.027), and lower platelet transfusion rate before delivery (57.6% vs. 97.9%, P < 0.001). Gestational weeks of delivery (37.6 [37–38.4] vs 37.1 [37–37.2] weeks, P = 0.001) were longer in the rhTPO group than in the control group. The rates of caesarean section, postpartum haemorrhage, foetal or neonatal complications, and complication types in both groups were similar (all P > 0.05). No liver or renal function impairment or thrombosis cases were observed in the rhTPO group. GEE analysis revealed that the baseline mean platelet volume (MPV) (odds ratio [OR]: 0.522, P = 0.002) and platelet-to-lymphocyte ratio (PLR) (OR: 1.214, P = 0.025) were predictors of response to rhTPO treatment.
Conclusion
rhTPO may be an effective and safe treatment option for pregnancies with ITP that do not respond to first-line treatment; it may have slightly prolonged the gestational age of delivery. Patients with a low baseline MPV and high baseline PLR may be more responsive to rhTPO treatment. The present study serves as a foundation for future research.
Funder
Foundation for Discipline Construction of Fujian Medical University Union Hospital
Joint Funds for the Innovation of Science and Technology, Fujian Province
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology
Reference36 articles.
1. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 207: Thrombocytopenia in Pregnancy. Obstet Gynecol. 2019;133(3):e181–93.
2. Comont T, Moulis G, Delavigne K, Cougoul P, Parant O, Guyard-Boileau B, Derumeaux H, Adoue D, Beyne-Rauzy O. Re: Severe Primary Autoimmune Thrombocytopenia (ITP) in Pregnancy: a national cohort study Primary immune thrombocytopenia management during pregnancy. A French study BJOG. 2018;125(5):629–30.
3. Cines DB, Levine LD. Thrombocytopenia in pregnancy. Blood. 2017;130(21):2271–7.
4. Kong Z, Qin P, Xiao S, Zhou H, Li H, Yang R, Liu X, Luo J, Li Z, Ji G, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017;130(9):1097–103.
5. Huang QS, Zhu XL, Qu QY, Liu X, Zhang GC, Su Y, Chen Q, Liu FQ, Sun XY, Liang MY, et al. Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. Am J Hematol. 2021;96(5):561–70.